Cork Teen's Desperate Plea: Irish Government Weighs Life-Changing Drug for Rare Illness
Context mode is active. Hover over any highlighted term to see its definition. Click a nested term to go deeper.
A 16-year-old Cork teenager, Paudie Coady, is making a heartfelt plea to the Irish government to fund Skyclarys, a critical drug that could slow the progression of his rare and devastating illness, Friedreich's Ataxia. The emotional appeal comes just days before the Health Service Executive (HSE) senior management is set to deliver a final decision on Tuesday, August 25, regarding the reimbursement of this life-changing medicine. This urgent situation is deeply personal for Paudie's family, who tragically lost his younger brother, Rory, to the same condition last September at the age of 13. The drug, also known as omaveloxolone, has been approved for use in the EU since February 2024 and in the US since February 2023, and is currently available in at least ten other European countries, including Germany and Slovakia, which has a similar population to Ireland. However, the HSE Drugs Group and the National Centre for Pharmacoeconomics (NCPE) have recommended against its public funding in Ireland, citing concerns over its clinical efficacy data and the significant annual cost of approximately €280,000 per patient. This has sparked widespread protests and a High Court challenge by another patient, Emily Felix, highlighting the growing frustration among the estimated 200 people living with Friedreich's Ataxia in Ireland. As the HSE final decision looms, patient advocacy groups like Rare Diseases Ireland are intensifying calls for a complete overhaul of Ireland's 'antiquated' rare disease drug reimbursement framework, which they argue lags significantly behind other European nations. While Health Minister Jennifer Carroll MacNeill has initiated a review process and aims for a 180-day reimbursement timeline by early 2029, the immediate fate of Skyclarys, and the hopes of Paudie Coady and many others, rests on Tuesday's critical announcement. This decision will not only impact current patients but also set a crucial precedent for access to other orphan medicine in Ireland.